By Steve Kennedy* and Anthony D. Sabatelli** — As discussed in our previous article, antibody-drug conjugates (ADCs) have emerged as a highly promising class of anti-cancer drugs, and significant technical innovations are being made in all three components of the ADC, i.e., the antibody, the drug payload, and the linker joining them. The linker has been an area of particular focus, both within pharmaceutical development and the patent space. The primary considerations for effective ADC linkers are their stability during circulation followed by release at the target site and their method of attachment to the antibody. The latter can determine…
View the original article here: Guest Post — Linking It Up: Antibody-Drug Conjugates
The article was originally posted on Patent Docs.
Each article is copyrighted to their original authors. We do not own any rights to the news or the images used. Whilst every care is taken to ensure that the news posts published are accurate, we cannot guarantee the authenticity of the news article on every occasion. There’s no copyright infringement intended. The news is for informational purposes only and does not provide legal advice.